A director at Tidewater Inc sold 351,940 shares at 106.954USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TULSA, Okla.--(BUSINESS WIRE)-- NGL Energy Partners LP (NYSE: NGL) announced today that it plans to issue its fiscal year ended March 31, 2024 earnings press release post-market close on Thursday, June 6, 2024. Members of NGL’s management team intend to host an earnings call following this release on Thursday, June 6, 2024 at 4:00 pm CDT to discuss its financial results. Analysts, investors, and other interested parties may join the webcast via the event link: or by dialing (888) 506-0062 and providing access code: 410412. An archived audio replay of the call will be available for 14 days, wh...
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14, at 4:30pm ET BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potentia...
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New Yor...
Autoscope Technologies Corporation Announces Financial Results and Dividend Declaration MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (OTCQX: AATC) today announced results for its quarter ended March 31, 2024. The Board of Directors has authorized and declared a quarterly cash dividend of $0.13 per share of its common stock. The dividend is payable on May 28, 2024 to the shareholders of record at the close of business on May 20, 2024. First Quarter 2024 Financial Summary Royalties increased 4 percent to $3.1 million compared to $3.0 million in the same...
BRT Apartments Corp. Files First Quarter 2024 Financial Statements GREAT NECK, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, announced that it has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2024 with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real e...
Photronics to Report Second Quarter Earnings BROOKFIELD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the second quarter of fiscal 2024 on Wednesday, May 22, 2024, before the market opens. Photronics will host a public conference call the same day at 8:30 a.m. Eastern time. During the call, company management will respond to questions concerning, but not limited to, the company's financial performance, business conditions, and industry outlook. Some responses may contain ...
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024 Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results ...
Tara L. French Elected to BCB Bancorp, Inc. and BCB Community Bank Boards of Directors BAYONNE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank” or “BCB”), today announced the election of Tara L. French to the Board of Directors of both BCB Bancorp, Inc. and BCB Community Bank, effective immediately. Ms. French previously was an officer at Northfield Bank until her retirement in June 2023. She joined Northfield in 2017 as the Chief Administrative Officer, and she was named Chief Risk Officer in September 2020....
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to highlight the ongoing clinical development of UNO HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinica...
Wrap Technologies Announces Exciting New Distributor Agreement with Kokusai Security MIAMI, April 26, 2024 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP), a global leader in innovative public safety technologies, is proud to announce a strategic distribution partnership with Kokusai Security Service, a leading provider of security solutions in the Asia-Pacific region. This partnership marks a significant milestone for both companies, as they join forces to bring cutting-edge public safety solutions to law enforcement agencies and security professionals across the region. Und...
MidWestOne Financial Group, Inc. Reports Financial Results for the First Quarter of 2024 IOWA CITY, Iowa, April 25, 2024 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“we”, “our”, or the "Company”) today reported results for the first quarter of 2024. First Quarter 2024 Summary1 Completed acquisition of Denver Bankshares, Inc. ("DNVB"), the related core banking system conversion, and closure of the legacy MidWestOne Denver banking office.Net income of $3.3 million, or $0.21 per diluted common share. Revenue was $44.5 million, comprised of net interest income of $...
BRT Apartments Corp. Announces Filing Date for First Quarter 2024 Earnings Results GREAT NECK, N. Y., April 25, 2024 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today announced it intends to file its Form 10-Q for the quarter ended March 31, 2024 with the Securities and Exchange Commission on or about May 9, 2024. The Company does not intend to conduct an earnings call to discuss the results. BRT is a real estate investment trust that ...
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the deli...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.